ACLARION, INC. Impairment of Intangible Assets, Finite-lived
ACLARION, INC. (ACON) reported Impairment of Intangible Assets, Finite-lived of $0 for the 6-month period ending 2023-06-30, per its 10-Q filed 2023-08-25.
Discontinued › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsFinitelived · last filed 2023-08-25
- ACLARION, INC. impairment of intangible assets, finite-lived for the quarter ending 2023-06-30 was $0.00.
- ACLARION, INC. impairment of intangible assets, finite-lived for the quarter ending 2023-03-31 was $0.00.
- ACLARION, INC. impairment of intangible assets, finite-lived for fiscal 2021 was $0.00.
| Period end | Impairment of Intangible Assets, Finite-lived 3 month | Impairment of Intangible Assets, Finite-lived 6 month | Impairment of Intangible Assets, Finite-lived 12 month |
|---|---|---|---|
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-25 | $0.00 10-Q · filed 2023-08-25 | |
| 2023-03-31 | $0.00 10-Q · filed 2023-07-03 | ||
| 2022-12-31 | $0.00 10-Q · filed 2023-08-25 | ||
| 2021-12-31 | $0.00 10-K/A · filed 2023-06-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |